Author:
Anota Amélie,Hamidou Zeinab,Paget-Bailly Sophie,Chibaudel Benoist,Bascoul-Mollevi Caroline,Auquier Pascal,Westeel Virginie,Fiteni Frederic,Borg Christophe,Bonnetain Franck
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference50 articles.
1. Beitz, J., Gnecco, C., & Justice, R. (1996). Quality-of-life end points in cancer clinical trials: The US food and drug administration perspective. Journal of the National Cancer Institute Monographs, (20), 7–9.
2. Johnson, J. R., & Temple, R. (1985). Food and drug administration requirements for approval of new anticancer drugs. Cancer Treatment Reports, 69(10), 1155–1159.
3. Lipscomb, J., Donaldson, M. S., Arora, N. K., Brown, M. L., Clauser, S. B., Potosky, A. L., et al. (2004). Cancer outcomes research. Journal of the National Cancer Institute Monographs, (33), 178–197.
4. Fairclough, D. L., Peterson, H. F., & Chang, V. (1998). Why are missing quality of life data a problem in clinical trials of cancer therapy? Statistics in Medicine, 17(5–7), 667–677.
5. Ross, L., Thomsen, B. L., Boesen, E. H., & Johansen, C. (2004). In a randomized controlled trial, missing data led to biased results regarding anxiety. Journal of Clinical Epidemiology, 57(11), 1131–1137.